- Home
- ICAD vs IMUX Comparison
ICAD vs IMUX Comparison
Compare ICAD & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICAD
- IMUX
- Stock Information
- Founded
- ICAD 1984
- IMUX 2016
- Country
- ICAD United States
- IMUX United States
- Employees
- ICAD N/A
- IMUX N/A
- Industry
- ICAD Medical/Dental Instruments
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- ICAD Health Care
- IMUX Health Care
- Exchange
- ICAD Nasdaq
- IMUX Nasdaq
- Market Cap
- ICAD 87.5M
- IMUX 90.3M
- IPO Year
- ICAD 1986
- IMUX N/A
- Fundamental
- Price
- ICAD $3.22
- IMUX $0.98
- Analyst Decision
- ICAD Hold
- IMUX Strong Buy
- Analyst Count
- ICAD 1
- IMUX 6
- Target Price
- ICAD N/A
- IMUX $13.20
- AVG Volume (30 Days)
- ICAD 1.5M
- IMUX 661.4K
- Earning Date
- ICAD 05-14-2025
- IMUX 05-07-2025
- Dividend Yield
- ICAD N/A
- IMUX N/A
- EPS Growth
- ICAD N/A
- IMUX N/A
- EPS
- ICAD N/A
- IMUX N/A
- Revenue
- ICAD $19,608,000.00
- IMUX N/A
- Revenue This Year
- ICAD $2.58
- IMUX N/A
- Revenue Next Year
- ICAD $14.78
- IMUX N/A
- P/E Ratio
- ICAD N/A
- IMUX N/A
- Revenue Growth
- ICAD 13.22
- IMUX N/A
- 52 Week Low
- ICAD $1.18
- IMUX $0.83
- 52 Week High
- ICAD $3.78
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- ICAD 74.47
- IMUX 45.24
- Support Level
- ICAD $1.59
- IMUX $0.86
- Resistance Level
- ICAD $3.38
- IMUX $1.01
- Average True Range (ATR)
- ICAD 0.17
- IMUX 0.09
- MACD
- ICAD 0.15
- IMUX -0.01
- Stochastic Oscillator
- ICAD 91.26
- IMUX 42.53
About ICAD iCAD Inc.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.